Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cervelo Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and psychiatric disorders. The company's lead program, CP-011, was an intranasal formulation of dihydroergotamine (DHE) designed for the acute treatment of cluster headaches. Founded by industry veterans from MAP Pharmaceuticals, Cervelo aimed to leverage specialized drug delivery technologies to improve the pharmacokinetic profile of established compounds. The company successfully advanced CP-011 into Phase 2 clinical trials to evaluate its efficacy and safety in patients with episodic or chronic cluster headache. However, the company has since ceased operations, and its development programs are no longer active.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cervelo Pharmaceuticals.